Enveric Biosciences Nears Key Clinical Milestone with Novel Drug Candidate

2026-02-24 01:00:20

Enveric Biosciences is advancing its lead drug candidate, EB-003, toward human clinical trials with an Investigational New Drug (IND) application targeted for 2026. EB-003 is a neuroplastogenic molecule designed to treat depression and anxiety disorders without hallucinogenic side effects. The company is in a strong financial position, being debt-free, which analysts view as a significant advantage as it prepares for the capital-intensive clinical phase.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.